Placebo-controlled pilot trial testing dose titration and intravenous, intramuscular and subcutaneous routes for ketamine in depression-Reference-Cited by-同舟云学术

Placebo-controlled pilot trial testing dose titration and intravenous, intramuscular and subcutaneous routes for ketamine in depression

Published:2016-03-30 Issue:1 Volume:134 Page:48-56
ISSN:0001-690X
Container-title:Acta Psychiatrica Scandinavica
language:en
Short-container-title:Acta Psychiatr Scand

Author:

Loo C. K.¹²³⁴,Gálvez V.¹²,O'Keefe E.¹,Mitchell P. B.¹²,Hadzi-Pavlovic D.¹²,Leyden J.³⁵,Harper S.³⁶,Somogyi A. A.⁷⁸,Lai R.⁹,Weickert C. S.¹¹⁰¹¹,Glue P.¹²

Affiliation:

1. School of Psychiatry; University of New South Wales; Sydney NSW Australia

2. Black Dog Institute; Randwick NSW Australia

3. Wesley Hospital; Kogarah NSW Australia

4. St George Hospital; Kogarah NSW Australia

5. Royal North Shore Hospital; St Leonards NSW Australia

6. University of New South Wales; Randwick NSW Australia

7. University of Adelaide; Adelaide SA Australia

8. Royal Adelaide Hospital; Adelaide SA Australia

9. Macquarie Hospital; Sydney NSW Australia

10. Schizophrenia Research Institute; Randwick NSW Australia

11. Neuroscience Research Australia; Randwick NSW Australia

12. Psychological Medicine; University of Otago; Dunedin New Zealand

Funder

Universitat de Barcelona

NSW Ministry of Health and the Macquarie Group Foundation

Schizophrenia Research Institute

University of New South Wales

Neuroscience Research Australia

National Health and Medical Research Council

Publisher

Wiley

Subject

Psychiatry and Mental health

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/acps.12572/fullpdf

Reference25 articles.

1. The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [(1)H]-MRS;Valentine;Psychiatry Res,2011

2. Antidepressant effects of ketamine in depressed patients;Berman;Biol Psychiatry,2000

3. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression;Diazgranados;Arch Gen Psychiatry,2010

4. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression;Zarate;Arch Gen Psychiatry,2006

5. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial;Murrough;Am J Psychiatry,2013

Cited by 174 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The quest for optimal ketamine dosing formula in treatment-resistant major depressive disorder;Pharmacological Reports;2024-08-26

2. Rapid and long-lasting effects of subcutaneous esketamine on suicidality: An open-label study in patients with treatment-resistant depression;Journal of Psychiatric Research;2024-08

3. Intravenous Ketamine as an Adjunctive Treatment for Dysthymia: A Case Report;Indian Journal of Private Psychiatry;2024-07-26

4. The Quest for Optimal Ketamine Dosing Formula in Treatment-Resistant Major Depressive Disorder;2024-07-12

5. Subcutaneous ketamine reduces suicide risk and improves functioning in depression: A proof-of-concept study;Psychiatry Research;2024-07